Treatments for BPH range from medication to surgery to minimally invasive surgical treatments (MIST), offering men a wide selection of options. However, many still come with side effects, limitations, or inconsistent outcomes.
Optilume is a groundbreaking, minimally invasive treatment that combines balloon dilation with a drug-coated delivery system. With promising clinical outcomes and growing patient success stories, Optilume is gaining attention as a potential game-changer in BPH management.
Here, we will explore how Optilume is redefining the future of BPH treatment and what it could mean for men seeking better, more effective options.
To begin with, what exactly is Optilume? Well, its full name is Optilume BPH TURBO (Trans-Urethral Radial-dilation Balloon Opening), and it is a new minimally invasive transurethral treatment option for men with symptomatic BPH, backed by a pivotal trial with 5-year outcomes.
Recently approved by the U.S. Food and Drug Administration, Optilume BPH TURBO is a unique minimally invasive surgical therapy (MIST) that combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel for the treatment of LUTS secondary to BPH. In simpler terms, it is a medication-coated balloon that combines specialized drug delivery technology with balloon dilation techniques.
Optilume is the first combination drug and device therapy offering the highest clinically reported flow rates of any minimal invasive therapy with immediate and sustained improvement in IPSS symptoms scores.
Unlike other MISTS, such as Rezum, iTind, or Urolift, the Optilume system is unique and completely different in speed of results, short catheterization, faster recovery, and no foreign implants. Patients may resume their normal activities within a few days following the procedure.
The recent FDA approval and published positive data will quickly establish Optilume as a new standard for physicians and men looking for rapid and sustained results in treating LUTS caused by BPH.
Optilume is a good option for men with BPH or LUTS who want to avoid surgery or medications. Below are the key benefits that distinguish it from other MISTS, positioning it as a leading treatment for BPH:
In July 2024, Dr. Kevin Zorn and the BPH Canada team in Montreal performed the world’s first office-based Optilume BPH procedure under local anesthesia. This milestone highlights the treatment’s potential for accessibility, offering a quick, in-office solution (under 30 minutes) to help men transition off long-term BPH medications, which often have sexual side effects and health risks.
Under Dr. Zorn’s care, all 15 cases have had successful balloon dilation delivered in under 30 minutes with no complications.
Optilume represents a promising step forward in the treatment of BPH with its impressive clinical outcomes and lasting symptom relief. Its innovative combination of balloon dilation and drug-coated technology sets it apart from other treatments, providing new hope for men seeking effective, low-risk solutions.
If you are a man experiencing any symptoms of BPH, do not hesitate to book a consultation with BPH Canada today. Our dedicated team of professionals are here for you.
AR
HY
ZH-CN
EN
DE
EL
IT
FA
PT
ES
TR
JP
